ArticlePloS one2020
Appetite and ghrelin levels in iron deficiency anemia and the effect of parenteral iron therapy: A longitudinal study.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Pilot pragmatic clinical trial of iron therapy in children with anemia of chronic kidney disease (FeTCh-CKD).Pediatric nephrology (Berlin, Germany) · 2026Trial
- Utilising the diagnostic criteria of paediatric feeding disorder: Updated findings from a population-based cohort study.Journal of pediatric gastroenterology and nutrition · 2026Observational
- Rapamycin and Post-Deficiency Dietary Recovery Reshape Antioxidant Response and Survival in Offspring of Iron-Deficient Mothers.Biological trace element research · 2025Article
- The effect of ferrous oral iron used in the treatment of iron deficiency on weight gain and appetite in adults: a prospective study.Primary health care research & development · 2025Observational
- Article
- The relationship between ghrelin and iron metabolism in beta thalassaemia major patients.Archives of medical science : AMS · 2025Article
- A Role for the Microbiota-Gut-Brain Axis in Avoidant/Restrictive Food Intake Disorder: A New Conceptual Model.The International journal of eating disorders · 2024Review
- Roles of ghrelin, hepcidin and HIF-2α in iron metabolism in iron deficiency anemia.Irish journal of medical science · 2024Article
- Dietary diversity and iron deficiency anemia among a cohort of singleton pregnancies: a cross-sectional study.BMC public health · 2024Article
- The prevalence and clinical significance of loss of appetite in older patients with chronic kidney disease.International urology and nephrology · 2023Article
- Nutritional studies in patients with β-thalassemia major: A short review.Acta bio-medica : Atenei Parmensis · 2023Review
- Factors associated with minimum dietary diversity failure among Indian children.Journal of nutritional science · 2022Article
- EFFECTS OF ORAL IRON REPLACEMENT ON GLUCOSE METABOLISM AND ANTHROPOMETRIC MEASURES IN PREMENOPAUSAL WOMEN WITH IRON DEFICIENCY ANEMIA: A PROSPECTIVE STUDY.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIron deficiency anemia (IDA) is associated with decreased appetite. The ghrelin hormone is one of the major regulators of appetite.
objectivesTo evaluate appetite and ghrelin levels in patients with IDA, and to investigate the change in appetite and ghrelin following intravenous iron therapy.
methodsA total of 56 IDA patients and 51 controls were included in the study. Both appetite and ghrelin were assessed at baseline and following intravenous iron therapy. These were assessed at corresponding time intervals in the control group. Appetite was assessed by the SNAQ score (Simplified Nutritional Appetite Questionnaire) and fasting ghrelin levels were assessed by acylated ghrelin (AG), unacylated ghrelin (UAG) and their respective ratio AG/UAG.
resultsIDA patients had significantly lower SNAQ scores, yet higher AG levels and higher AG/UAG ratios compared to healthy controls; the mean SNAQ scores were 12.56 ± 3.45 and 16.1 ± 2, respectively (P<0.01); the median AG levels were 57.5 pg/ml and 43 pg/ml respectively (P = 0.007); and the median AG/UAG ratios were 0.48 and 0.25 respectively (P = 0.04). On multivariate linear regression analysis, IDA remained independently associated with decreased SNAQ score (β = -0.524, P<0.001) and increased acylated ghrelin (β = 0.289, P = 0.013). After IDA was treated, SNAQ scores increased significantly by a mean of 2 points. AG and AG/UAG ratios decreased significantly by a mean of -18.44 pg/ml and -0.2 respectively. The control group showed no significant change in SNAQ scores or ghrelin at corresponding time intervals.
conclusionsIDA patients have a reduced appetite and paradoxically elevated ghrelin hormone activity compared to healthy controls. Treating IDA enhances appetite and lowers ghrelin levels. Future studies are needed to explore the mechanism of this paradoxical ghrelin activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.